The expression of FOS-like antigen 1 in head and neck squamous cell carcinoma and its clinical significance

doi:10.3969/j.issn.1009-976X.2020.03.012

Abstract

Abstract: Objective To detect the expression of FOS-like antigen 1 （FOSL1） in head and neck squamous cell carcinoma （HNSC） and to investigate the correlation between its expression and the clinical data or prognosis of HNSC patients. Methods The expression of FOSL1 in 98 HNSC patients and the adjacent normal tissues were predicted by UALCAN microarray database. The expression of FOSL1 in head and neck squamous cell carcinoma tissues and normal tissues was further detected by immunohistochemistry （IHC）. The relationship between the FOSL1 expression and clinical characteristics was analyzed bytest, and Kaplan-Meier methods were used to analysis the correlation between FOSL1 protein and HNSC patients' survival. Results UALCAN database and IHC assays showed that the expression of FOSL1 protein in HNSC was significantly higher than that in normal tissues （P<0.05）. The expression of FOSL1 protein was closely correlated with tumor size, lymph node metastasis, pathological grading and HPV status （P<0.05）. Survival analysis showed that the survival rate of FOSL1 high expression group was significantly lower than that of FOSL1 low expression group （P<0.05）. Conclusion FOSL1 is involved in the development and progression of HNSC, and may be useful in evaluating the prognosis.

Key words: prognosis, head and neck squamous cell carcinoma, immunohistochemistry, FOSL1

摘要： 目的探讨FOS样抗原1（FOSL1）蛋白在头颈鳞癌中的表达及其与临床病理特点及患者预后的关系。方法使用UALCAN数据库预测FOSL1在头颈鳞癌（HNSC）中的表达情况,收集98例头颈鳞癌患者,采用免疫组化法检测头颈鳞癌及其癌旁正常组织中FOSL1蛋白的表达,并分析其表达与临床特征的关系。结果 UALCAN数据库及免疫组化结果均显示FOSL1蛋白在头颈鳞癌中的相对表达量明显高于癌旁正常组织（P<0.05）;FOSL1的表达与头颈鳞癌的大小、淋巴结转移、病理分级及HPV状态密切相关（P<0.05）。Kaplan-Meier分析显示FOSL1高表达组HNSC患者总积生存率明显低于低表达组HNSC患者（P< 0.05）。结论 FOSL1蛋白参与头颈鳞癌的发生发展,FOSL1的表达水平有助于头颈鳞癌恶性程度的评价及预后的判断。

关键词: 预后, FOSL1, 头颈鳞癌, 免疫组化

CLC Number:

R739.9

GAO Xiao-lin, XIU Xia, QIU Ping-ping, ZHANG DU-he-yi, XIE Shu-le, LIN Zhao-yu. The expression of FOS-like antigen 1 in head and neck squamous cell carcinoma and its clinical significance[J]. Lingnan Modern Clinics in Surgery, 2020, 20(03): 319-323.

高晓琳, 修霞, 邱萍萍, 张杜合一, 谢舒乐, 林钊宇. FOS样抗原1在头颈鳞癌中的表达及临床意义[J]. 岭南现代临床外科, 2020, 20(03): 319-323.

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
[2] Xie SL, Fan S, Zhang SY, et al.SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway[J]. Int J Cancer, 2018, 142(6):1252-1265.
[3] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[4] Elangovan IM, Vaz M, Tamatam CR, et al.FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation[J]. Am J Respir Cell Mol Biol, 2018,58(5):625-635.
[5] Han Y, Zhao X, Sun Y, et al.Effects of FOSL1 silencing on osteosarcoma cell proliferation, invasion and migration through the ERK/AP-1 signaling pathway[J]. J Cell Physiol, 2019,234(4):3598-3612.
[6] Cai B, Wu J, Yu X, et al.FOSL1 inhibits type Ⅰ interferon responses to malaria and viral infections by blocking TBK1 and TRAF3/TRIF interactions[J]. mBio, 2017,8(1): e02161-16.
[7] Shaulian E.AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise?[J] Cell Signal, 2010, 22(6):894-899.
[8] Jiang X, Xie H, Dou Y, et al.Expression and function of FOSL1 protein in tumors[J]. Mol Biol Rep, 2020,47(1):737-752.
[9] Young MR, Colburn NH.Fra-1 a target for cancer prevention or intervention[J]. Gene, 2006,379:1-11.
[10] Kawabata K, Murakami A, Ohigashi H.Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells[J]. BiosciBiotechnolBiochem, 2005, 69(2):307-314.
[11] Galvagni F, Orlandini M, Oliviero S.Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration[J]. Cell AdhMigr, 2013,7(5):408-411.
[12] Letson C, Padron E.Non-canonical transcriptional consequences of BET inhibition in cancer[J]. Pharmacol Res, 2019,150:104508.
[13] Vallejo A, Perurena N, Guruceaga E, et al.An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer[J]. Nat Commun, 2017,8:14294.
[14] Luo YZ, He P, Qiu MX.FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway[J]. Eur Rev Med Pharmacol Sci, 2018,22(24):8609-8615.
[15] Chandrashekar DS, Bashel B, Balasubramanya SAH, et al.UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.